HutchMed Completes $537 Million Hong Kong IPO for Oncology Drugs
June 30, 2021 at 05:46 AM EDT
HutchMed, a Shanghai novel drug company, completed a $537 million IPO on the Hong Kong exchange, its third global listing. The company is also listed on London 's AIM exchange and NASDAQ. HutchMed (formerly Hutchison Chi-Med) has three novel approved oncology drugs in China , and it has seven more candidates in development. Following the IPO, its shares rose 20% ($6.49) to $40.02 in early trading on NASDAQ, giving the company a market capitalization of $6 billion. More details.... Stock Symbols: (NASDQ/AIM: HCM; HK: 13) Share this with colleagues: // //
